RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome
Apoptosis, necroptosis and pro-inflammatory NF-κB-dependent signaling are repressed by receptor-interacting serine/threonine-protein kinase 1 (RIPK1). A recent paper in Immunity describes a small molecule inducing the proteolytic degradation of RIPK1. In preclinical experiments, this RIPK1 inhibitor...
Saved in:
| Main Authors: | Jonathan G. Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, Guido Kroemer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2425465 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy
by: Peng Liu, et al.
Published: (2024-12-01) -
Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma
by: Jonathan G. Pol, et al.
Published: (2024-12-01) -
Immunogenic oncolysis by tigilanol tiglate
by: Jonathan G. Pol, et al.
Published: (2024-12-01) -
Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors
by: Lucillia Bezu, et al.
Published: (2023-12-01) -
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference
by: Pierre-Antoine Laurent, et al.
Published: (2025-12-01)